Cannabigerol (CBG) Cannabinoid Research

Cannabigerol (CBG) Research Dashboard

75

Primary Studies

66

Related Studies

141

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind human trials

1

Clinical human trials

Pre-Clinical Studies

14

Meta-analyses/Reviews

21

Animal studies

39

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 141 studies associated with Cannabigerol (CBG).

Here is a small sampling of Cannabigerol (CBG) studies by title:


Components of the Cannabigerol (CBG) Research Dashboard

  • Top medical conditions associated with Cannabigerol (CBG)
  • Proven effects in clinical trials for Cannabigerol (CBG)
  • Receptors associated with Cannabigerol (CBG)
  • Individual study details for Cannabigerol (CBG)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Cannabigerol (CBG)

Description of Cannabigerol (CBG)

Cannabigerol was isolated, characterized, and synthetized by R. Mechoulan and Y. Gaoni in 1964. CBG is non-psychoactive. It is the central biosynthetic precursor to many cannabinoids. For that reason CBG is often referenced as "mother of all cannabinoids."

Other Names:

Cannabigerol

Geranylolivetol plus numerous other supplier-based synonyms.


IUPAC Name: 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentylbenzene-1,3-diol


Molecular Formula: C21H32O2


Source–PubChem

Cannabigerol (CBG) Properties and Effects

CBG is:


  • An inhibitor of voltage-gated sodium (Nav) channels (M. Ghovanloo et al., 2022

  • Non-pychoactive (R. Mechoulam et al., 1970)

  • Muscle relaxant

  • Analgesia

  • Sedative

  • May be anti-proliferative in cases of prostate and colorectal cancer

  • Antibacterial (MRSA)

  • Appetite stimulant (in cases of anorexia, cachexia)

  • Anti-parasitical (leishmania)

  • Pre-clinical trials suggest potential benefits in treating neurological disorders such as Huntington's Disease.

Cannabigerol (CBG) Receptor Binding

Endocannabinoid system (ECS) and CBG:


Endocannabinoidome (eCBome) and CBG:


  • TRPV1 (significant agonist)

  • TRPA1 (significant agonist)

  • TRPM8 [inhibitor (antagonist)]

  • 5HT1A serotonin receptors (moderate inhibitor)

  • Alpha-2-andrenergic-receptor sites (agonist)




Ki legend:



  • Full/strong agonist Ki ~1-9nM

  • Moderate agonist Ki ~10-99nM

  • Weak agonist Ki ~100-999nM

  • Very weak agonist Ki ~1,000-up nM


(The reader is reminded that a smaller Ki is associated with the strongest effects.)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.